Clinical Pharmacokinetics of Cannabinoids
نویسنده
چکیده
Absorption and metabolism of tetrahydrocannabinol (THC) vary as a function of route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes, while psychotropic effects start within seconds to a few minutes, reach a maximum after 15 to 30 minutes, and taper off within 2 to 3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30 to 90 minutes, reach their maximum after 2 to 3 hours, and last for about 4 to 12 hours, depending on dose and specific effect. The initial volume of distribution of THC is small for a lipophilic drug, equivalent to the plasma volume of about 2.5-3 L, reflecting high protein binding of 95-99%. The steady state volume of distribution has been estimated to be about 100 times larger, in the range of about 3.5 L per kg of body weight. The lipophility of THC with high binding to tissue and in particular to fat, the major long-term storage site, causes a change of distribution pattern over time. Only about 1% of THC administered IV is found in the brain at the time of peak psychoactivity. THC crosses the placenta and small amounts penetrate into the breast milk. Metabolism of THC occurs mainly in the liver by microsomal hydroxylation and oxidation catalyzed by enzymes of the cytochrome P-450 complex. In man, the C-11 carbon is the major site attacked. Hydroxylation results in 11-hydroxy-THC (11-OH-THC) and further oxidation to 11-nor-9-carboxy-THC (THC-COOH), which may be glucuronated to THC-COOH beta-glucuronide. Pharmacologically, 11-OH-THC shows a similar profile as THC while THC-COOH is devoid of psychotropic effects. With oral administration higher amounts of 11-OH-THC are formed than with inhalation, reaching similar plasma levels as its parent drug, and contributing significantly to the overall effects of THC. Franjo Grotenhermen, MD, is affiliated with nova-Institut, Goldenbergstraβe 2, D-50354 Hürth, Germany (E-mail: [email protected]). Journal of Cannabis Therapeutics, Vol. 3(1) 2003 http://www.haworthpressinc.com/store/product.asp?sku=J175 2003 by The Haworth Press, Inc. All rights reserved. 10.1300/J175v03n01_02 3 Metabolic interaction between THC and the non-psychotropic cannabidiol (CBD) is based on inhibition of the cytochrome P-450-3A enzyme by CBD. Repeated administration of all cannabinoids causes induction of some cytochrome P-450 isoenzymes which may result in interactions with other medical and non-medical drugs that are using the same enzymes for metabolism. [Article copies available for a fee from The Haworth Document Delivery Service: 1-800-HAWORTH. E-mail address: Website: 2003 by The Haworth Press, Inc. All rights reserved.]
منابع مشابه
Treatment of Neuropathic Pain: Opioids, Cannabinoids, and Topical Agents - Printer-friendly version
1. To review the mechanisms and eff ects of opioids, cannabinoids, and topical agents in neuropathic pain. 2. To review clinically relevant pharmacokinetics and pharmacodynamics of opioids, cannabinoids, and topical agents in patients with neuropathic pain. 3. To review the clinical evidence for the use of opi-oids, cannabinoids, and topical agents in neuro-pathic pain.
متن کاملPharmacological actions and therapeutic uses of cannabis and cannabinoids.
This review highlights the pharmacology, pharmacokinetics, pharmacological actions, therapeutic uses and adverse effects of cannabinoids. The effect of cannabinoids on anaesthesia is mentioned briefly. Important advances have taken place in cannabinoid research over the last few years and have led to the discovery of novel ligands. The possible clinical applications of these ligands and the dir...
متن کاملPharmacokinetics and pharmacodynamics of cannabinoids.
Delta(9)-Tetrahydrocannabinol (THC) is the main source of the pharmacological effects caused by the consumption of cannabis, both the marijuana-like action and the medicinal benefits of the plant. However, its acid metabolite THC-COOH, the non-psychotropic cannabidiol (CBD), several cannabinoid analogues and newly discovered modulators of the endogenous cannabinoid system are also promising can...
متن کاملCannabinoids in late-onset Alzheimer's disease.
Given the lack of effective treatments for late-onset Alzheimer's disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing interest in the medicinal uses of cannabinoids, the bioactive components of the cannabis plant, including the treatment ...
متن کاملClinical Pharmacology of Fluconazole in Neonates: Effects and Pharmacokinetics
Fluconazole is commonly used both to prevent and to treat invasive neonatal Candida albicans infection. This drug is a potent, selective, triazole inhibitor of the fungal enzymes involved in ergosterol synthesis. It is largely excreted unchanged in the urine. In infants with a birth weight
متن کاملClinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
Tacrolimus, a cornerstone of immunosuppressive therapy in solid organ transplantation, has a narrow therapeutic range with considerable inter-individual and intra-individual pharmacokinetic variability. To date, there is no information on the pharmacokinetics of tacrolimus in Iranian liver transplant recipients. This study was designed to determine pharmacokinetic properties of orally administe...
متن کامل